Switzerland Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Region: Trend Forecast and Growth Opportunity

April 2023 | 170 pages | ID: S5CD946A84C7EN
GMD Research

Abstracts

Switzerland clinical trials market is projected to grow by 6.8% annually in the forecast period and reach $824.5 million by 2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments.

Highlighted with 80 tables and 70 figures, this 170-page report “Switzerland Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Switzerland clinical trials market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Switzerland market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Switzerland clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Region.

Based on Product Category, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.

• Trials of Drugs
• Small Molecule Drugs
• Vaccines
• Cell & Gene Therapy
• Other Drugs
• Trials of Devices
• Trials of Procedures

Based on Phase, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.

• Phase I
• Phase II
• Phase III
• Phase IV

By Design, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.

• Interventional Studies
• Randomized Control Trial
• Adaptive Clinical Trial
• Non-randomized Control Trial
• Observational Studies
• Cohort Study
• Case Control Study
• Cross Sectional Study
• Ecological Study
• Expanded Access Trials

By Service Type, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.

• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Clinical Trial Supply & Logistic Services
• Decentralized Clinical Trial Services
• Medical Device Testing Services
• Other Clinical Trial Services

By Indication, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.

• Oncology
• Infectious Diseases
• Cardiology
• Obesity
• Diabetes
• Neurology
• Immunology
• Pain Management
• Other Indications

By End User, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.

• Pharmaceutical and Biotechnological Companies
• Clinical Research Organizations
• Clinical Testing Laboratories
• Other End Users

Geographically, the following national/local markets are fully investigated:

• Aargau [Argovia]
• Appenzell Outer Rhodes
• Appenzell Inner Rhodes
• Basel-Landschaft
• Basel-Stadt [Basel-City]
• Bern
• Fribourg
• Gen?ve [Geneva]
• Glarus
• Graubьnden [Grisons]
• Jura
• Luzern
• Neuchвtel
• Nidwalden [Nidwald]
• Obwalden [Obwald]
• Schaffhausen
• Schwyz
• Solothurn
• St. Gallen
• Thurgau [Thurgovia]
• Ticino
• Uri
• Valais
• Vaud
• Zug
• Zьrich [Zurich]

For each key region, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

Accell Clinical Research LLC

Charles River Laboratories

ClinDatrix Inc

Clinipace

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

ICON PLC

IQVIA Holdings, Inc.

Laboratory Corporation of America (Covance Inc.)

Novo Nordisk AS

PAREXEL International Corporation

Pfizer Inc.

Pharmaceutical Product Development LLC

PhlexSwitzerland

PRA Health Sciences

Sanofi SA

SGS SA (SGS Life Sciences)

Syneos Health Inc.

Wuxi AppTec Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
  2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF SWITZERLAND MARKET BY PRODUCT CATEGORY

3.1 Market Overview by Product Category
3.2 Trials of Drugs
  3.2.1 Small Molecule Drugs
  3.2.2 Vaccines
  3.2.3 Cell & Gene Therapy
  3.2.4 Other Drugs
3.3 Trials of Devices
3.4 Trials of Procedures

4 SEGMENTATION OF SWITZERLAND MARKET BY PHASE

4.1 Market Overview by Phase
4.2 Phase I
4.3 Phase II
4.4 Phase III
4.5 Phase IV

5 SEGMENTATION OF SWITZERLAND MARKET BY DESIGN

5.1 Market Overview by Design
5.2 Interventional Studies
  5.2.1 Randomized Control Trial
  5.2.2 Adaptive Clinical Trial
  5.2.3 Non-randomized Control Trial
5.3 Observational Studies
  5.3.1 Cohort Study
  5.3.2 Case Control Study
  5.3.3 Cross Sectional Study
  5.3.4 Ecological Study
5.4 Expanded Access Trials

6 SEGMENTATION OF SWITZERLAND MARKET BY SERVICE TYPE

6.1 Market Overview by Service Type
6.2 Protocol Designing
6.3 Site Identification
6.4 Patient Recruitment
6.5 Laboratory Services
6.6 Bioanalytical Testing Services
6.7 Clinical Trial Data Management Services
6.8 Clinical Trial Supply & Logistic Services
6.9 Decentralized Clinical Trial Services
6.10 Medical Device Testing Services
6.11 Other Clinical Trial Services

7 SEGMENTATION OF SWITZERLAND MARKET BY INDICATION

7.1 Market Overview by Indication
7.2 Oncology
7.3 Infectious Diseases
7.4 Cardiology
7.5 Obesity
7.6 Diabetes
7.7 Neurology
7.8 Immunology
7.9 Pain Management
7.10 Other Indications

8 SEGMENTATION OF SWITZERLAND MARKET BY END USER

8.1 Market Overview by End User
8.2 Pharmaceutical and Biotechnological Companies
8.3 Clinical Research Organizations
8.4 Clinical Testing Laboratories
8.5 Other End Users

9 SEGMENTATION OF SWITZERLAND MARKET BY REGION

10 COMPETITIVE LANDSCAPE

10.1 Overview of Key Vendors
10.2 New Product Launch, Partnership, Investment, and M&A
10.3 Company Profiles
Accell Clinical Research LLC
Charles River Laboratories
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America (Covance Inc.)
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
Phlexglobal
PRA Health Sciences
Sanofi SA
SGS SA (SGS Life Sciences)
Syneos Health Inc.
Wuxi AppTec Inc.
RELATED REPORTS

List Of Tables

LIST OF TABLES:

Table 1. Snapshot of Switzerland Clinical Trials Market in Balanced Perspective, 2022-2031
Table 2. Total Number of Registered Clinical Studies Worldwide, 2010-2021
Table 3. World Economic Outlook, 2021-2031
Table 4. World Economic Outlook, 2021-2023
Table 5. Scenarios for Economic Impact of Ukraine Crisis
Table 6. World Health Spending by Region, $ bn, 2013-2020
Table 7. Main Product Trends and Market Opportunities in Switzerland Clinical Trials Market
Table 8. Switzerland Clinical Trials Market by Product Category, 2021-2031, $ mn
Table 9. Switzerland Clinical Trials Market: Trials of Drugs by Drug Type, 2021-2031, $ mn
Table 10. Switzerland Clinical Trials Market by Phase, 2021-2031, $ mn
Table 11. Switzerland Clinical Trials Market by Design, 2021-2031, $ mn
Table 12. Switzerland Clinical Trials Market: Interventional Studies by Segment, 2021-2031, $ mn
Table 13. Switzerland Clinical Trials Market: Observational Studies by Segment, 2021-2031, $ mn
Table 14. Switzerland Clinical Trials Market by Service Type, 2021-2031, $ mn
Table 15. Switzerland Clinical Trials Market by Indication, 2021-2031, $ mn
Table 16. Number of Oncology Clinical Trials and Number of Patients in Switzerland by Cancer Type, as of March 2023
Table 17. Switzerland Clinical Trials Market by End User, 2021-2031, $ mn
Table 18. Switzerland Clinical Trials Market by Region, 2021-2031, % of Revenue
Table 19. Switzerland Clinical Trials Market by Region, 2021-2031, $ mn
Table 20. Accell Clinical Research LLC: Company Snapshot
Table 21. Accell Clinical Research LLC: Business Segmentation
Table 22. Accell Clinical Research LLC: Product Portfolio
Table 23. Charles River Laboratories: Company Snapshot
Table 24. Charles River Laboratories: Product Portfolio
Table 25. Charles River Laboratories: Breakdown of Revenue by Division
Table 26. Charles River Laboratories: Breakdown of Revenue by Region
Table 27. ClinDatrix Inc: Company Snapshot
Table 28. Clinipace: Company Snapshot
Table 29. Clinipace: Product Portfolio
Table 30. Eli Lilly and Company: Company Snapshot
Table 31. Eli Lilly and Company: Pharmaceutical Brands
Table 32. Eli Lilly and Company: Clinical Trial Service
Table 33. Eli Lilly and Company: Breakdown of Revenue by Therapeutic Area
Table 34. Eli Lilly and Company: Breakdown of Revenue by Region
Table 35. F. Hoffmann-La Roche: Company Snapshot
Table 36. F. Hoffmann-La Roche: Clinical Trial Service
Table 37. F. Hoffmann-La Roche: Business Segmentation
Table 38. F. Hoffmann-La Roche: Revenue by Region
Table 39. ICON Plc: Company Snapshot
Table 40. ICON Plc: Business Segmentation
Table 41. ICON Plc: Product Portfolio
Table 42. ICON Plc: Revenue by Region, 2020, %
Table 43. IQVIA Holdings Inc.: Company Snapshot
Table 44. IQVIA Holdings Inc.: Business Segmentation
Table 45. IQVIA Holdings Inc.: Revenue by Region, 2020, %
Table 46. IQVIA Holdings Inc.: Product Portfolio
Table 47. Covance Inc.: Company Snapshot
Table 48. Covance Inc.: Product Portfolio
Table 49. Covance Inc.: Revenue by Region, 2020, %
Table 50. Novo Nordisk: Company Snapshot
Table 51. Novo Nordisk: Product Portfolio
Table 52. Novo Nordisk: Breakdown of Revenue by Business Segment
Table 53. Novo Nordisk: Breakdown of Revenue by Region
Table 54. PAREXEL International Corporation: Company Snapshot
Table 55. PAREXEL International Corporation: Business Segmentation
Table 56. PAREXEL International Corporation: Revenue by Region, 2018, %
Table 57. PAREXEL International Corporation: Product Portfolio
Table 58. Pfizer Inc.: Company Snapshot
Table 59. Pfizer Inc.: Business Segmentation
Table 60. Pfizer Inc.: Breakdown of Revenue by Product Category
Table 61. Pfizer Inc.: Breakdown of Revenue by Region
Table 62. Pfizer Inc.: Product Portfolio
Table 63. Pfizer Inc.: Revenue, 2018-2020, $ bn
Table 64. Pharmaceutical Product Development LLC (PPD): Company Snapshot
Table 65. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Division
Table 66. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Region
Table 67. Phlexglobal: Company Snapshot
Table 68. PRA Health Sciences Inc.: Company Snapshot
Table 69. PRA Health Sciences Inc.: Business Segmentation
Table 70. PRA Health Sciences Inc.: Revenue by Region, 2018, %
Table 71. Sanofi: Company Snapshot
Table 72. Sanofi: Business Segmentation
Table 73. Sanofi: Breakdown of Revenue by Region
Table 74. SGS SA (SGS Life Sciences): Company Snapshot
Table 75. SGS SA (SGS Life Sciences): Business Segmentation
Table 76. SGS SA (SGS Life Sciences): Revenue by Region, 2018, %
Table 77. Syneos Health Inc.: Company Snapshot
Table 78. Syneos Health Inc.: Business Segmentation
Table 79. Syneos Health Inc.: Revenue by Region, 2020, %
Table 80. WuXi AppTec Inc.: Company Snapshot

List Of Figures

LIST OF FIGURES:

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Switzerland Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2031
Figure 4. Switzerland Clinical Trials Market, 2021-2031, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Switzerland Clinical Trials Market
Figure 7. Percentage of Trial Participants by Country, 2015-2019
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060
Figure 11. Primary Restraints and Impact Factors of Switzerland Clinical Trials Market
Figure 12. Investment Opportunity Analysis
Figure 13. Porter’s Fiver Forces Analysis of Switzerland Clinical Trials Market
Figure 14. Breakdown of Switzerland Clinical Trials Market by Product Category, 2021-2031, % of Revenue
Figure 15. Switzerland Addressable Market Cap in 2023-2031 by Product Category, Value ($ mn) and Share (%)
Figure 16. Switzerland Clinical Trials Market by Product Category: Trials of Drugs, 2021-2031, $ mn
Figure 17. Switzerland Clinical Trials Market by Trials of Drugs: Small Molecule Drugs, 2021-2031, $ mn
Figure 18. Switzerland Clinical Trials Market by Trials of Drugs: Vaccines, 2021-2031, $ mn
Figure 19. Switzerland Clinical Trials Market by Trials of Drugs: Cell & Gene Therapy, 2021-2031, $ mn
Figure 20. Switzerland Clinical Trials Market by Trials of Drugs: Other Drugs, 2021-2031, $ mn
Figure 21. Switzerland Clinical Trials Market by Product Category: Trials of Devices, 2021-2031, $ mn
Figure 22. Switzerland Clinical Trials Market by Product Category: Trials of Procedures, 2021-2031, $ mn
Figure 23. Breakdown of Switzerland Clinical Trials Market by Phase, 2021-2031, % of Sales Revenue
Figure 24. Switzerland Addressable Market Cap in 2023-2031 by Phase, Value ($ mn) and Share (%)
Figure 25. Switzerland Clinical Trials Market by Phase: Phase I, 2021-2031, $ mn
Figure 26. Switzerland Clinical Trials Market by Phase: Phase II, 2021-2031, $ mn
Figure 27. Switzerland Clinical Trials Market by Phase: Phase III, 2021-2031, $ mn
Figure 28. Switzerland Clinical Trials Market by Phase: Phase IV, 2021-2031, $ mn
Figure 29. Breakdown of Switzerland Clinical Trials Market by Design, 2021-2031, % of Sales Revenue
Figure 30. Switzerland Addressable Market Cap in 2023-2031 by Design, Value ($ mn) and Share (%)
Figure 31. Switzerland Clinical Trials Market by Design: Interventional Studies, 2021-2031, $ mn
Figure 32. Switzerland Clinical Trials Market by Interventional Studies: Randomized Control Trial, 2021-2031, $ mn
Figure 33. Switzerland Clinical Trials Market by Interventional Studies: Adaptive Clinical Trial, 2021-2031, $ mn
Figure 34. Switzerland Clinical Trials Market by Interventional Studies: Non-randomized Control Trial, 2021-2031, $ mn
Figure 35. Switzerland Clinical Trials Market by Design: Observational Studies, 2021-2031, $ mn
Figure 36. Switzerland Clinical Trials Market by Observational Studies: Cohort Study, 2021-2031, $ mn
Figure 37. Switzerland Clinical Trials Market by Observational Studies: Case Control Study, 2021-2031, $ mn
Figure 38. Switzerland Clinical Trials Market by Observational Studies: Cross Sectional Study, 2021-2031, $ mn
Figure 39. Switzerland Clinical Trials Market by Observational Studies: Ecological Study, 2021-2031, $ mn
Figure 40. Switzerland Clinical Trials Market by Design: Expanded Access Trials, 2021-2031, $ mn
Figure 41. Breakdown of Switzerland Clinical Trials Market by Service Type, 2021-2031, % of Revenue
Figure 42. Switzerland Addressable Market Cap in 2023-2031 by Service Type, Value ($ mn) and Share (%)
Figure 43. Switzerland Clinical Trials Market by Service Type: Protocol Designing, 2021-2031, $ mn
Figure 44. Switzerland Clinical Trials Market by Service Type: Site Identification, 2021-2031, $ mn
Figure 45. Switzerland Clinical Trials Market by Service Type: Patient Recruitment, 2021-2031, $ mn
Figure 46. Switzerland Clinical Trials Market by Service Type: Laboratory Services, 2021-2031, $ mn
Figure 47. Switzerland Clinical Trials Market by Service Type: Bioanalytical Testing Services, 2021-2031, $ mn
Figure 48. Switzerland Clinical Trials Market by Service Type: Clinical Trial Data Management Services, 2021-2031, $ mn
Figure 49. Switzerland Clinical Trials Market by Service Type: Clinical Trial Supply & Logistic Services, 2021-2031, $ mn
Figure 50. Switzerland Clinical Trials Market by Service Type: Decentralized Clinical Trial Services, 2021-2031, $ mn
Figure 51. Switzerland Clinical Trials Market by Service Type: Medical Device Testing Services, 2021-2031, $ mn
Figure 52. Switzerland Clinical Trials Market by Service Type: Other Clinical Trial Services, 2021-2031, $ mn
Figure 53. Breakdown of Switzerland Clinical Trials Market by Indication, 2021-2031, % of Revenue
Figure 54. Switzerland Addressable Market Cap in 2023-2031 by Indication, Value ($ mn) and Share (%)
Figure 55. Switzerland Clinical Trials Market by Indication: Oncology, 2021-2031, $ mn
Figure 56. Switzerland Clinical Trials Market by Indication: Infectious Diseases, 2021-2031, $ mn
Figure 57. Switzerland Clinical Trials Market by Indication: Cardiology, 2021-2031, $ mn
Figure 58. Switzerland Clinical Trials Market by Indication: Obesity, 2021-2031, $ mn
Figure 59. Switzerland Clinical Trials Market by Indication: Diabetes, 2021-2031, $ mn
Figure 60. Switzerland Clinical Trials Market by Indication: Neurology, 2021-2031, $ mn
Figure 61. Switzerland Clinical Trials Market by Indication: Immunology, 2021-2031, $ mn
Figure 62. Switzerland Clinical Trials Market by Indication: Pain Management, 2021-2031, $ mn
Figure 63. Switzerland Clinical Trials Market by Indication: Other Indications, 2021-2031, $ mn
Figure 64. Breakdown of Switzerland Clinical Trials Market by End User, 2021-2031, % of Revenue
Figure 65. Switzerland Addressable Market Cap in 2023-2031 by End User, Value ($ mn) and Share (%)
Figure 66. Switzerland Clinical Trials Market by End User: Pharmaceutical and Biotechnological Companies, 2021-2031, $ mn
Figure 67. Switzerland Clinical Trials Market by End User: Clinical Research Organizations, 2021-2031, $ mn
Figure 68. Switzerland Clinical Trials Market by End User: Clinical Testing Laboratories, 2021-2031, $ mn
Figure 69. Switzerland Clinical Trials Market by End User: Other End Users, 2021-2031, $ mn
Figure 70. Growth Stage of Switzerland Clinical Trials Industry over the Forecast Period